Company news

GSK plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA approval on Arexvy for 50-59 at risk

August 29, 2024

SENKU Designation for Bepirovirsen in Japan

August 28, 2024

Nucala approved in Japan for use in CRSwNP

August 28, 2024

B7-H3 ADC US FDA Breakthrough Therapy Designation

August 20, 2024

FDA Expands Jemperli Approval

August 2, 2024

CHMP positive opinion on Arexvy for 50-59 at risk

July 29, 2024

Blenrep EMA Filing Acceptance

July 19, 2024

GSK and CureVac collaboration restructured

July 3, 2024

Omjjara approved in Japan for myelofibrosis

June 24, 2024

EMA validates Jemperli marketing authorisation

June 24, 2024

FDA approves Arexvy for adults 50-59 at risk

June 10, 2024

Unprecedented results in Jemperli trial continue

June 3, 2024

ASCO positive Blenrep DREAMM-8 trial results

June 3, 2024

Positive phase III asthma results for depemokimab

May 21, 2024

GSK completes sale of shares in Haleon plc

May 17, 2024

GSK announces intention to sell shares in Haleon

May 16, 2024

US FDA accepts new indication filing for Jemperli

April 24, 2024

GSK announces additional EAGLE-1 results

April 17, 2024

Results from long-term data relating to Shingrix

April 17, 2024

Amendment - Director/PDMR Shareholding

April 16, 2024

FDA accepts GSK meningitis vaccine candidate file

April 16, 2024

Replacement - Total Voting Rights

April 4, 2024

New Phase III Jemperli data in endometrial cancer

March 18, 2024

GSK announces positive Blenrep DREAMM-8 results

March 7, 2024

ViiV LAI vs oral SOC data in adherence-challenged

March 6, 2024

GSK Annual Report 2023 on Form 20-F

March 5, 2024

New ViiV LA formulation potential 4-month dosing

March 5, 2024

GSK publishes Annual Report 2023

March 1, 2024

GSK announces positive EAGLE-1 headline results

February 26, 2024

ViiV LAI superior to orals in adherence-challenged

February 21, 2024

Julie Brown - External Appointment

February 20, 2024

GSK completes acquisition of Aiolos Bio

February 15, 2024

Director/PDMR Shareholding - Replacement

February 13, 2024

US FDA Fast Track designation for bepirovirsen

February 12, 2024

FDA accepts Arexvy filing for adults 50-59 at risk

February 6, 2024

Shingrix 18+ at risk China filing review accepted

February 6, 2024

GSK presents positive DREAMM-7 phase III data

February 6, 2024

EMA accepts Arexvy filing for adults 50-59 at risk

January 29, 2024

European Commission authorises Omjjara in the EU

January 29, 2024

Holding(s) in Company

January 18, 2024

Nucala approved in China for use in severe asthma

January 10, 2024

GSK enters agreement to acquire Aiolos Bio

January 9, 2024

Publication of EMTN Suppl.Prospcts

December 20, 2023

Jemperli plus Zejula Trial Meets Endpoint

December 18, 2023

Japan accepts Arexvy filing for at risk adults

December 12, 2023

Jemperli plus chemotherapy EU authorisation

December 11, 2023

GSK publishes provisional 2024 dividend dates

December 4, 2023

GSK announces positive DREAMM-7 headline results

November 27, 2023

GSK receives positive CHMP opinion for momelotinib

November 13, 2023

Jemperli trial meets overall survival endpoint

October 30, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 181 decks. Every deck is listed under its year.